Implementation of an Outpatient HD-MTX Initiative

INTRODUCTION: Methotrexate (MTX) a folate antagonist is often given in high doses (≥500 mg/m(2)) to treat a variety of disease processes. While inpatient administration has been the norm, outpatient administration, has been shown to be safe, effective, and patient centered. Here in we describe devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Sokol, Kelsey, Yuan, Kelley, Piddoubny, Maria, Sweeney, Ellen, Delengowski, Anne, Fendler, Katlin, Espinosa, Gloria, Alberto, Judith, Galanis, Patricia, Gung, Carol, Stokley, Meghan, George, Mercy, Harris, Mary, Martinez-Outschoorn, Ubaldo, Alpdogan, Onder, Porcu, Pierluigi, Binder, Adam F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811119/
https://www.ncbi.nlm.nih.gov/pubmed/35127480
http://dx.doi.org/10.3389/fonc.2021.773397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811119/
https://www.ncbi.nlm.nih.gov/pubmed/35127480
http://dx.doi.org/10.3389/fonc.2021.773397

Ejemplares similares